Curated News
By: NewsRamp Editorial Staff
September 18, 2026
Regentis CEO Discusses GelrinC Progress and Market Potential on BioMedWire Podcast
TLDR
- Regentis Biomaterials targets a 470,000-case U.S. knee cartilage market with GelrinC, already approved in Europe, offering a first-mover advantage.
- GelrinC is a cell-free hydrogel implant that degrades in the knee, enabling surrounding cells to regenerate cartilage through a controlled, synchronous process.
- Regentis Biomaterials develops regenerative solutions like GelrinC to restore knee health and enhance quality of life for patients with cartilage injuries.
- Regentis Biomaterials' GelrinC is an off-the-shelf hydrogel for knee cartilage repair, currently in U.S. pivotal trials with enrollment completion expected around year-end.
Impact - Why it Matters
The development of GelrinC(R) could revolutionize the treatment of cartilage knee injuries, offering a much-needed off-the-shelf solution for the approximately 470,000 untreated cases annually in the U.S. If successful, it may reduce the need for invasive surgeries and provide a more accessible option for patients. For investors, Regentis' advancements in clinical trials and European commercialization efforts could translate into significant market opportunities and potential revenue growth. As the regenerative medicine field continues to evolve, Regentis' progress highlights the growing intersection of biotechnology and orthopedic care, with implications for patient outcomes and the broader healthcare industry.
Summary
In a recent episode of The BioMedWire Podcast, Regentis Biomaterials (NYSE American: RGNT) Executive Chairman and CEO Dr. Ehud Geller shared insights on the company's regenerative medicine platform and its lead product, GelrinC(R), a cell-free, off-the-shelf hydrogel designed to treat cartilage injuries in the knee. Geller highlighted that GelrinC(R) is already approved for marketing in Europe and is currently undergoing a U.S. pivotal clinical trial, with efforts to expand clinical sites and complete enrollment by the end of the year. He also noted a significant U.S. market opportunity, with an estimated 470,000 untreated cases annually, and discussed the company's strategy to advance European commercialization through partnerships with distribution systems and major orthopedic companies.
Regentis Biomaterials is dedicated to developing innovative tissue repair solutions, with an initial focus on orthopedic treatments. The Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC(R) is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. With no off-the-shelf treatment currently available for cartilage knee repair in the U.S., GelrinC(R) addresses a substantial unmet medical need. The company's efforts to expand clinical trials and commercialize in Europe signal a promising step forward in regenerative medicine.
For investors and industry observers, Regentis' progress with GelrinC(R) could represent a significant advancement in orthopedic care. The successful completion of the U.S. pivotal trial and European commercialization could position the company as a key player in the regenerative medicine market. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis CEO Discusses GelrinC Progress and Market Potential on BioMedWire Podcast
